Granted Patent B2

US 10,227,289 · App. 13/696,028 · Granted Mar 12, 2019

Abstract

Claims (11)

1. A method of treating a lung disease in a mammal, comprising delivering a biocompatible hydrogel polymer to a target site in the lung of the mammal, wherein the biocompatible hydrogel polymer gels to at the target site in the lung and wherein the biocompatible hydrogel polymer consists of an aqueous buffer, a therapeutic agent, and a polymer prepared from monomers consisting of:

(a) 8-ARM-20k-NH2 PEG amine, 4-ARM-20k-AA acetate amine, and 8-ARM-PEG-SG monomer; or

(b) 8-ARM-20k-NH2 PEG amine, 8-ARM-20k-AA acetate amine, and 8-ARM-PEG-SG monomer and wherein the biocompatible hydrogel polymer dos not contain blood or protein.

2. The method of claim 1 , wherein the lung disease is a cancer of a lung, wherein the target site in the lung of the mammal is a site of the cancer of the lung, and wherein the therapeutic agent is an anticancer agent.

3. The method of claim 1 , wherein the lung disease is mesothelioma, wherein the target site in the lung of the mammal is a site of the mesothelioma, and wherein the therapeutic agent is an anticancer agent.

4. The method of claim 1 , wherein the lung disease is emphysema, wherein the target site in the lung of the mammal is a site affected by the emphysema, wherein the therapeutic agent is an antiviral agent, antibacterial agent, antifungal agent, immunosuppressant agent, or anti-inflammatory agent, wherein the biocompatible hydrogel polymer blocks an air passage or changes the lung surface tension, and wherein a portion of the lung is controllably collapsed.

5. The method of claim 1 , wherein the lung disease is a bronchopleural fistula, wherein the target site in the lung of the mammal is a site of a fistula in the lung of the mammal, wherein the therapeutic agent is an antiviral agent, antibacterial agent, antifungal agent, immunosuppressant agent, or anti-inflammatory agent, wherein the biocompatible hydrogel polymer gels at the site of the fistula, and wherein the biocompatible hydrogel polymer seals the fistula.

6. The method of claim 2 , wherein the anticancer agent is selected from the group consisting of docetaxel, paclitaxel, carboplatin, cisplatin, oxaliplatin, satraplatin, etoposide, gemcitabine, pemetrexed, diphtheria toxin, adenylate cyclase toxin, verotoxin-1, α-toxin, α-hemolysin, curare, and α-cobratoxin.

7. The method of claim 3 , wherein the anticancer agent is selected from the group consisting of docetaxel, paclitaxel, carboplatin, cisplatin, oxaliplatin, satraplatin, etoposide, gemcitabine, pemetrexed, diphtheria toxin, adenylate cyclase toxin, verotoxin-1, α-toxin, α-hemolysin, curare, and α-cobratoxin.

8. The method of claim 1 , wherein the biocompatible hydrogel polymer does not contain biological materials.

9. The method of claim 1 , wherein the biocompatible hydrogel gels to at the target site in the lung and has a degradation time of more than 60 days.

Assignments (8)